User profiles for S. Mockus

Susan M. Mockus

Precision Biomarker Laboratories - Cedars-Sinai
Verified email at cshs.org
Cited by 1192

Liquefied petroleum gas (LPG) as a medium-term option in the transition to sustainable fuels and transport

L Raslavičius, A Keršys, S Mockus, N Keršienė… - … and Sustainable Energy …, 2014 - Elsevier
… Propane׳s particular characteristics make it ideally suited to the contemporary energy-…
Due to its heterogeneous emergence and development, the EU-27׳s liquefied petroleum gas …

Advances in the molecular characterization of tryptophan hydroxylase

SM Mockus, KE Vrana - Journal of Molecular Neuroscience, 1998 - Springer
… Inhibition of TPH byl-DOPA may have implications for depression in Parkinson’s disease (PD)
patients. In addition, TPH inactivation by nitric oxide may be involved in amphetamine-…

mTOR inhibitors in castration-resistant prostate cancer: a systematic review

CM Statz, SE Patterson, SM Mockus - Targeted oncology, 2017 - Springer
… Partial metabolic responses (PMR) were determined using FDG-PET to assess mTOR
inhibition owing to mTOR’s ability to stimulate glucose uptake [44]. Post treatment with everolimus …

The comparative toxicogenomics database: update 2011

AP Davis, BL King, S Mockus, CG Murphy… - Nucleic acids …, 2010 - academic.oup.com
… website even more user-friendly, including a redesigned homepage to make navigation
easier and more intuitive, a ‘Downloads’ menu tab that allows users to download all of CTD’s

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes

PA VanderLaan, D Rangachari, SM Mockus, V Spotlow… - Lung cancer, 2017 - Elsevier
Introduction The degree and duration of response to epidermal growth factor receptor (EGFR)
inhibitors in EGFR mutated lung cancer are heterogeneous. We hypothesized that the …

[HTML][HTML] A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

…, R Dienstmann, D Chakravarty, XS Li, S Mockus… - Nature …, 2020 - nature.com
Precision oncology relies on accurate discovery and interpretation of genomic variants,
enabling individualized diagnosis, prognosis and therapy selection. We found that six prominent …

[HTML][HTML] The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies

…, CM Statz, D Durkin, A Lakshminarayana, SM Mockus - Human genomics, 2016 - Springer
… A fundamental challenge to precision medicine is the ability to easily connect a patient’s
genetic variants with a therapeutic approach, which could include either FDA-approved targeted …

[HTML][HTML] Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance

…, A Harper, J Malcolm, MS McAndrews, SM Mockus… - BMC cancer, 2019 - Springer
Background Understanding mechanisms underlying specific chemotherapeutic responses
in subtypes of cancer may improve identification of treatment strategies most likely to benefit …

Standardizing gene product nomenclature—a call to action

…, AB Carter, ML Gulley, SM Mockus… - Proceedings of the …, 2021 - National Acad Sciences
… In this scenario, italics signifies a gene symbol, whereas nonitalics signifies the encoded
protein(s). Thus, the italic term PDCD1 indicates the PDCD1 gene, whereas the nonitalic term …

Mechanism of SNARE protein binding and regulation of Cav2 channels by phosphorylation of the synaptic protein interaction site

CT Yokoyama, SJ Myers, J Fu, SM Mockus… - Molecular and Cellular …, 2005 - Elsevier
… These results indicate that the CaMKII phosphorylation site(s) that regulate SNARE protein
interactions reside within Ca v 2.2[773–859] and Ca v 2.2[832–905] and therefore support a …